Search

Your search keyword '"Samaniego, Felipe"' showing total 1,123 results
Start Over Author "Samaniego, Felipe"
1,123 results on '"Samaniego, Felipe"'

1. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial

Author

Gunther, Jillian R, Xu, Jie, Bhutani, Manoop S, Strati, Paolo, Fang, Penny Q, Wu, Susan Y, Dabaja, Bouthaina S, Dong, Wenli, Bhosale, Priya R, Flowers, Christopher R, Nair, Ranjit, Malpica Castillo, Luis, Fayad, Luis, Iyer, Swaminathan P, Parmer, Simrit, Wang, Michael, Lee, Hun Ju, Samaniego, Felipe, Westin, Jason, Ahmed, Sairah, Nze, Chijioke C, Jain, Preetesh, Neelapu, Sattva S, Rodriguez, Maria A, Chihara, Dai, Nastoupil, Loretta J, and Pinnix, Chelsea C

Published
2024
Full Text
View/download PDF

2. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Cherng, Hua-Jay J., Sun, Ryan, Sugg, Bryant, Irwin, Russell, Yang, Haopeng, Le, Cao Cuong, Deng, Qing, Fayad, Luis, Fowler, Nathan H., Parmar, Simrit, Steiner, Raphael, Hagemeister, Fredrick, Nair, Ranjit, Lee, Hun Ju, Rodriguez, Maria, Samaniego, Felipe, Iyer, Swaminathan P., Flowers, Christopher R., Wang, Linghua, Nastoupil, Loretta J., Neelapu, Sattva S., Ahmed, Sairah, Strati, Paolo, Green, Michael R., and Westin, Jason

Published
2022
Full Text
View/download PDF

3. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo

Published
2022
Full Text
View/download PDF

4. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Author

Wang, Michael L, Jain, Preetesh, Zhao, Shuangtao, Lee, Hun Ju, Nastoupil, Loretta, Fayad, Luis, Ok, Chi Young, Kanagal-Shamanna, Rashmi, Hill, Holly A, Yao, Yixin, Hagemeister, Fredrick B, Westin, Jason R, Fowler, Nathan, Samaniego, Felipe, Steiner, Raphael, Nair, Ranjit, Iyer, Swaminathan P, Navsaria, Lucy, Badillo, Maria, Feng, Lei, Xuelin, Huang, Nogueras Gonzalez, Graciela M, Xu, Guofan, Wagner-Bartak, Nicolaus, Thirumurthi, Selvi, Santos, David, Tang, Guilin, Lin, Pei, Wang, Sa A, Jorgensen, Jeff, Yin, C Cameron, Li, Shaoying, Patel, Keyur P, Vega, Francisco, Medeiros, L Jeffery, Flowers, Christopher R, and Wang, Linghua

Published
2022
Full Text
View/download PDF

6. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Author

Davids, Matthew S., O'Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., and Flinn, Ian W.

Published
2021
Full Text
View/download PDF

7. Clinical Factors Associated with Failure to Manufacture Commercial CAR-T Cell Products Among LBCL Patients

Author

Patel, Romil D, primary, Feng, Lei, additional, Gurumurthi, Ashwath, additional, Westin, Jason R., additional, Nastoupil, Loretta J., additional, Nair, Ranjit, additional, Iyer, Swaminathan P., additional, Fayad, Luis, additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Nieto, Yago, additional, Oran, Dr. Betul, additional, Hawkins, Mrs. Misha, additional, Chihara, Dai, additional, Adkins, Sherry, additional, Shpall, Elizabeth J., additional, Ramdial, Jeremy, additional, Strati, Paolo, additional, Hosing, Chitra, additional, Neelapu, Sattva S., additional, and Ahmed, Sairah, additional

Published
2024
Full Text
View/download PDF

8. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Author

Greenbaum, Uri, Strati, Paolo, Saliba, Rima M., Torres, Janet, Rondon, Gabriela, Nieto, Yago, Hosing, Chitra, Srour, Samer A., Westin, Jason, Fayad, Luis E., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Flowers, Christopher R., Tummala, Sudhakar, Ramdial, Jeremy L., Yalniz, Fevzi F., Hawkins, Misha, Rezvani, Katayoun, Champlin, Richard E., Shpall, Elizabeth J., Neelapu, Sattva S., Kebriaei, Partow, and Ahmed, Sairah

Published
2021
Full Text
View/download PDF

11. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

12. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Author

Gordon, Max J., primary, Feng, Lei, additional, Strati, Paolo, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Samaniego, Felipe, additional, Marques‐Piubelli, Mario L., additional, Vega Vazquez, Francisco, additional, Parra Cuentas, Edwin R., additional, Solis‐Soto, Luisa M., additional, Ma, Wencai, additional, Wang, Jing, additional, Claret, Linda, additional, Averill, Barbara, additional, Ibanez, Karina, additional, Fayad, Luis E., additional, Flowers, Christopher R., additional, Green, Michael R., additional, Davis, R. Eric, additional, Neelapu, Sattva S., additional, Fowler, Nathan H., additional, and Nastoupil, Loretta J., additional

Published
2023
Full Text
View/download PDF

13. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Author

Deng, Qing, Han, Guangchun, Puebla-Osorio, Nahum, Ma, Man Chun John, Strati, Paolo, Chasen, Beth, Dai, Enyu, Dang, Minghao, Jain, Neeraj, Yang, Haopeng, Wang, Yuanxin, Zhang, Shaojun, Wang, Ruiping, Chen, Runzhe, Showell, Jordan, Ghosh, Sreejoyee, Patchva, Sridevi, Zhang, Qi, Sun, Ryan, Hagemeister, Frederick, Fayad, Luis, Samaniego, Felipe, Lee, Hans C., Nastoupil, Loretta J., Fowler, Nathan, Eric Davis, R., Westin, Jason, Neelapu, Sattva S., Wang, Linghua, and Green, Michael R.

Published
2020
Full Text
View/download PDF

14. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B, Fayad, Luis, Romaguera, Jorge E, Fowler, Nathan, Fanale, Michelle A, Kwak, Larry W, Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J, Wierda, William, Fu, Kai, Chan, Wing C, Vose, Julie M, O'Brien, Susan, Davis, Richard E, and Burger, Jan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Rare Diseases, Lymphoma, Hematology, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Adenine, Antineoplastic Agents, B-Cell Activation Factor Receptor, Biomarkers, Tumor, Cell Line, Tumor, Chemokine CCL3, Chemokine CCL4, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, Humans, Lymphoma, Large B-Cell, Diffuse, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Signal Transduction, chemokines, diffuse large B-cell lymphoma, lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant B cells secrete the chemokines CCL3 and CCL4 to attract accessory cells to the tissue microenvironment. We measured CCL3 and CCL4 serum concentrations in 102 patients with newly diagnosed DLBCL by enzyme-linked immunosorbent assay, investigated their prognostic impact and validated our findings in an independent cohort of 51 patient samples. We also tested CCL3 and CCL4 secretion by DLBCL cells, and the influence of BTK inhibitors on the secretion of these chemokines. High CCL3 (≥40 pg/ml) serum concentrations correlated with higher international prognostic index, lactate dehydrogenase and β2 microglobulin, as did CCL4 (≥180 pg/ml) with advanced Ann Arbor stages. High CCL3 levels correlated with significantly shorter progression-free and overall survival. The in vitro studies demonstrated that activated B cell-like, but not germinal centre B cell-like DLBCL cells, secrete high levels of CCL3 and CCL4 after BCR triggering, which was exquisitely sensitive to BCR pathway inhibition. These findings support CCL3 and CCL4 protein concentrations as biomarkers for BCR pathway activation and prognosis in DLBCL.

Published
2015

16. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Author

Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., and Davis, R. Eric

Subjects
MUCOSA-associated lymphoid tissue lymphoma, LENALIDOMIDE, BRUTON tyrosine kinase, RITUXIMAB, FOLLICULAR lymphoma
Abstract

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study. Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months. Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash. Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257). After 5 years of follow‐up from a phase 2 clinical trial of ibrutinib, lenalidomide, and rituximab in previously untreated patients with follicular and marginal zone lymphoma, the 5‐year progression‐free survival rate was 59.7% and the overall survival rate was 97.9%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. CREBBP lysine acetyltransferase domain mutations create zombie enzymes that alter chromatin loading dynamics and prevent EP300 redundancy

Author

Yang, Haopeng, primary, Zhang, Wenchao, additional, Ravanmehr, Vida, additional, Mechaly, Ariel, additional, Regad, Leslie, additional, Haouz, Ahmed, additional, Chen, Ruidong, additional, Henderson, Jared, additional, Rojas, Estela, additional, Wilson, Ashley, additional, Parsons, Sydney, additional, Nastoupil, Loretta, additional, Davis, Richard Eric, additional, Deng, Qing, additional, Samaniego, Felipe, additional, Rodrigues-Lima, Fernando, additional, and Green, Michael R, additional

Published
2023
Full Text
View/download PDF

18. Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

24. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Author

Fanale, Michelle A., Cheah, Chan Yoon, Rich, Amy, Medeiros, L.Jeffrey, Lai, Chao-Ming, Oki, Yasuhiro, Romaguera, Jorge E., Fayad, Luis E., Hagemeister, F.B., Samaniego, Felipe, Rodriguez, Maria A., Neelapu, Sattva S., Lee, Hun J., Nastoupil, Loretta, Fowler, Nathan H., Turturro, Francesco, Westin, Jason R., Wang, Michael L., McLaughlin, Peter, Pinnix, Chelsea C., Milgrom, Sarah A., Dabaja, Bouthaina, Horowitz, Sandra B., and Younes, Anas

Published
2017
Full Text
View/download PDF

26. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Author

Westin, Jason, primary, Davis, R. Eric, additional, Feng, Lei, additional, Hagemeister, Fredrick, additional, Steiner, Raphael, additional, Lee, Hun Ju, additional, Fayad, Luis, additional, Nastoupil, Loretta, additional, Ahmed, Sairah, additional, Rodriguez, Alma, additional, Fanale, Michelle, additional, Samaniego, Felipe, additional, Iyer, Swaminathan P., additional, Nair, Ranjit, additional, Oki, Yasuhiro, additional, Fowler, Nathan, additional, Wang, Michael, additional, Ma, Man Chun John, additional, Vega, Francisco, additional, McDonnell, Timothy, additional, Pinnix, Chelsea, additional, Griffith, Donna, additional, Lu, Yang, additional, Tewari, Sanjit, additional, Sun, Ryan, additional, Scott, David W., additional, Flowers, Christopher R., additional, Neelapu, Sattva, additional, and Green, Michael R., additional

Published
2023
Full Text
View/download PDF

27. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

Author

Wang, Michael L, Lee, Hun, Chuang, Hubert, Wagner-Bartak, Nicolaus, Hagemeister, Frederick, Westin, Jason, Fayad, Luis, Samaniego, Felipe, Turturro, Francesco, Oki, Yasuhiro, Chen, Wendy, Badillo, Maria, Nomie, Krystle, Rosa, Maria DeLa, Zhao, Donglu, Lam, Laura, Addison, Alicia, Zhang, Hui, Young, Ken H, Li, Shaoying, Santos, David, Medeiros, L Jeffrey, Champlin, Richard, Romaguera, Jorge, and Zhang, Leo

Published
2016
Full Text
View/download PDF

29. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial

Author

Oki, Yasuhiro, Ewer, Michael S., Lenihan, Daniel J., Fisch, Michael J., Hagemeister, Fredrick B., Fanale, Michelle, Romaguera, Jorge, Pro, Barbara, Fowler, Nathan, Younes, Anas, Astrow, Alan B., Huang, Xuelin, Kwak, Larry W., Samaniego, Felipe, McLaughlin, Peter, Neelapu, Sattva S., Wang, Michael, Fayad, Luis E., Durand, Jean-Bernard, and Alma Rodriguez, M.

Published
2015
Full Text
View/download PDF

30. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Author

Strati, Paolo, primary, Li, Xubin, additional, Deng, Qing, additional, Feng, Lei, additional, Sun, Ryan, additional, Jallouk, Andrew, additional, Adkins, Sherry, additional, Cain, Taylor, additional, Johncy, Swapna, additional, Steiner, Raphael E, additional, Ahmed, Sairah, additional, Chihara, Dai, additional, Fayad, Luis, additional, Iyer, Swaminathan Padmanabhan, additional, Horowitz, Sandra B., additional, Nehlsen, Rachel, additional, Nastoupil, Loretta J., additional, Nair, Ranjit, additional, Hassan, Ahmed, additional, Daoud, Taher, additional, Hawkins, Misha, additional, Samaniego, Felipe, additional, Rodriguez, Maria Alma, additional, Shpall, Elizabeth J, additional, Kebriaei, Partow, additional, Flowers, Christopher R., additional, Hong, David, additional, Westin, Jason, additional, Neelapu, Sattva S., additional, and Green, Michael R., additional

Published
2022
Full Text
View/download PDF

31. A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Author

Samaniego, Felipe, primary, Sadiq, Ahad A., additional, Mahadevan, Daruka, additional, Koontz, Michael Z., additional, Villasboas, Jose C., additional, Burke, John M., additional, Reid, Erin G, additional, Cherry, Mohamad, additional, Melear, Jason, additional, Priego, Victor, additional, Cobb, Patrick, additional, Cull, Elizabeth H., additional, Conkling, Paul, additional, Cosgrove, David, additional, Roeker, Lindsey E., additional, Nguyen Haney, Donna, additional, Hu, Jia, additional, Sinha, Ranjeet Kumar, additional, Rice, William G, additional, and Bejar, Rafael, additional

Published
2022
Full Text
View/download PDF

32. Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Author

Soumerai, Jacob D., primary, Diefenbach, Catherine S., additional, Samaniego, Felipe, additional, Kumar, Abhijeet, additional, Tsai, Michaela L., additional, Asch, Adam S., additional, Jagadeesh, Deepa, additional, Kenkre, Vaishalee P., additional, Lossos, Izidore S., additional, Salman, Huda, additional, Awan, Farrukh T., additional, Miao, Lu, additional, Ghalie, Richard G., additional, and Zelenetz, Andrew D., additional

Published
2022
Full Text
View/download PDF

33. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma

Author

Pinnix, Chelsea C., primary, Dabaja, Bouthaina S., additional, Gunther, Jillian R., additional, Fang, Penny, additional, Wu, Susan, additional, Ahmed, Sairah, additional, Steiner, Raphael E, additional, Nair, Ranjit, additional, Strati, Paolo, additional, Westin, Jason, additional, Fayad, Luis, additional, Iyer, Swami P., additional, Rodriguez, Maria Alma, additional, Lee, Hun Ju, additional, Samaniego, Felipe, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Feng, Lei, additional, Flowers, Christopher R., additional, Neelapu, Sattva S., additional, and Nastoupil, Loretta J., additional

Published
2022
Full Text
View/download PDF

34. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

Author

Agbedia, Owhofasa O., primary, Prakash, Rishab, additional, Xu, Jie, additional, Becnel, Melody R., additional, Nair, Ranjit, additional, Steiner, Raphael E, additional, Feng, Lei, additional, Lee, Hun Ju, additional, Strati, Paolo, additional, Ahmed, Sairah, additional, Parmar, Simrit, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Westin, Jason, additional, Nastoupil, Loretta J., additional, Vo, Ann, additional, Samaniego, Felipe, additional, Fowler, Nathan H., additional, Saini, Neeraj, additional, Khouri, Issa F., additional, Im, Jin S., additional, Fayad, Luis, additional, Jain, Preetesh, additional, Wang, Michael L., additional, Miranda, Roberto N., additional, Vega, Francisco, additional, Medeiros, Jeffrey, additional, Oki, Yasuhiro, additional, Flowers, Christopher R., additional, Neelapu, Sattva S., additional, and Iyer, Swaminathan P., additional

Published
2022
Full Text
View/download PDF

36. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Author

Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

37. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Author

Westin, Jason R, Chu, Fuliang, Zhang, Min, Fayad, Luis E, Kwak, Larry W, Fowler, Nathan, Romaguera, Jorge, Hagemeister, Fredrick, Fanale, Michelle, Samaniego, Felipe, Feng, Lei, Baladandayuthapani, Veerabhadran, Wang, Zhiqiang, Ma, Wencai, Gao, Yanli, Wallace, Michael, Vence, Luis M, Radvanyi, Laszlo, Muzzafar, Tariq, Rotem-Yehudar, Rinat, Davis, R Eric, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

39. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, additional, Marques-Piubelli, Mario L., additional, Dai, Enyu, additional, Dang, Minghao, additional, Ma, Man Chun John, additional, Li, Xubin, additional, Yang, Haopeng, additional, Henderson, Jared, additional, Kudryashova, Olga, additional, Meerson, Mark, additional, Isaev, Sergey, additional, Kotlov, Nikita, additional, Nomie, Krystle J., additional, Bagaev, Alexander, additional, Parra, Edwin R., additional, Solis Soto, Luisa M., additional, Parmar, Simrit, additional, Hagemeister, Fredrick B., additional, Ahmed, Sairah, additional, Iyer, Swaminathan P., additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Fayad, Luis, additional, Lee, Hun, additional, Fowler, Nathan H., additional, Flowers, Christopher R., additional, Strati, Paolo, additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta J., additional, Vega, Francisco, additional, Wang, Linghua, additional, and Green, Michael R., additional

Published
2022
Full Text
View/download PDF

41. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial

Author

Westin, Jason R., Thompson, Michael A., Cataldo, Vince D., Fayad, Luis E., Fowler, Nathan, Fanale, Michelle A., Neelapu, Saatva, Samaniego, Felipe, Romaguera, Jorge, Shah, Jatin, McLaughlin, Peter, Pro, Barbara, Kwak, Larry W., Sanjorjo, Perpetua, Murphy, William A., Jimenez, Camillo, Toth, Bela, Dong, Wenli, and Hagemeister, Fredrick B.

Published
2013
Full Text
View/download PDF

44. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Author

Chihara, Dai, Fanale, Michelle A., Miranda, Roberto N., Noorani, Mansoor, Westin, Jason R., Nastoupil, Loretta J., Hagemeister, Fredrick B., Fayad, Luis E., Romaguera, Jorge E., Samaniego, Felipe, Turturro, Francesco, Lee, Hun J., Neelapu, Sattva S., Rodriguez, M. Alma, Wang, Michael, Fowler, Nathan H., Davis, Richard E., Medeiros, L. Jeffrey, Hosing, Chitra, Nieto, Yago L., and Oki, Yasuhiro

Published
2017
Full Text
View/download PDF

45. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Author

Wang, Michael, Fayad, Luis, Wagner-Bartak, Nicolaus, Zhang, Liang, Hagemeister, Fredrick, Neelapu, Sattva S, Samaniego, Felipe, McLaughlin, Peter, Fanale, Michelle, Younes, Anas, Cabanillas, Fernando, Fowler, Nathan, Newberry, Kate J, Sun, Luhong, Young, Ken H, Champlin, Richard, Kwak, Larry, Feng, Lei, Badillo, Maria, Bejarano, Maria, Hartig, Kimberly, Chen, Wendy, Chen, Yiming, Byrne, Catriona, Bell, Neda, Zeldis, Jerome, and Romaguera, Jorge

Published
2012
Full Text
View/download PDF

46. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Author

Khouri, Issa F., Saliba, Rima M., Erwin, William D., Samuels, Barry I., Korbling, Martin, Medeiros, L. Jeffrey, Valverde, Rosamar, Alousi, Amin M., Anderlini, Paolo, Bashir, Qaiser, Ciurea, Stefan, Gulbis, Alison M., de Lima, Marcos, Hosing, Chitra, Kebriaei, Partow, Popat, Uday R., Fowler, Nathan, Neelapu, Sattva S., Samaniego, Felipe, Champlin, Richard E., and Macapinlac, Homer A.

Published
2012
Full Text
View/download PDF

47. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Author

Younes, Anas, Oki, Yasuhiro, McLaughlin, Peter, Copeland, Amanda R., Goy, Andre, Pro, Barbara, Feng, Lei, Yuan, Ying, Chuang, Hubert H., Macapinlac, Homer A., Hagemeister, Fredrick, Romaguera, Jorge, Samaniego, Felipe, Fanale, Michelle A., Dabaja, Bouthaina Shbib, Rodriguez, Maria A., Dang, Nam, Kwak, Larry W., Neelapu, Sattva S., and Fayad, Luis E.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results